Ray Pharma
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi pharmaceutical manufacturer operated by the Rahimtoola Group, with an ISO-certified manufacturing facility at S.I.T.E.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Ray Pharma (Pvt.) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- Rahimtoola House, 38-C Khayaban-e-Shahbaz, DHA Phase VI, Karachi, Pakistan
- Website
- raypharma.com.pk ↗
- Phone
- +92 21 35243301-06
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Aclic | Zoledronic acid | 5 mg/100 mL | IV infusion | 100ml vial | 086784 | PKR 30,876.73 | PKR 308.77/mL | Near median |
| Altis DS | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 1x8's | 076680 | PKR 563.04 | PKR 70.38/tablet | 10% above median |
| Altis Plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 1x4's | 076681 | PKR 469.20 | PKR 117.30/tablet | 8% above median |
| Crixan | Clarithromycin | 125 mg | Dry suspension | 60ml | 076588 | PKR 460.56 | PKR 7.68/mL | No comparator |
| Genticyn Eye/Ear Gentamycin Sulphate 0.003Source observed | — | — | — | 7.5ml | 000482Official source ↗ | No indexed price | — | — |
| Genticyn Gentamycin Sulphate | Gentamicin | 80 mg | Injection | 2 x 2ml | 000500 | PKR 118.66 | PKR 29.67/mL | 115% above median |
| Genticyn Genticyn | Gentamicin | 40 mg | Injection | 3 x 1ml | 000500 | PKR 124.62 | PKR 41.54/mL | 189% above median |
| Genticyn HC | Gentamicin + Hydrocortisone | 0.3 % + 1 % | Eye/ear drops | 7.5ml | 004298 | PKR 63.02 | PKR 8.40/mL | No comparator |
| Genticyn Paediatric | Gentamicin | 20 mg/2 mL | Injection | 5 x 2ml | 010098 | PKR 130.29 | PKR 13.03/mL | 41% above median |
| Locadent | Lidocaine + Adrenaline | 2% + 1:80,000 | Injection | 50"s Ampoules | 079959 | PKR 1,132.57 | — | No comparator |
| Mikaray | Amikacin | 100 mg/2 mL | Injection | 1s | 053313 | PKR 84.68 | PKR 84.68/vial/unit | 25% above median |
| Mikaray | Amikacin | 250 mg/2 mL | Injection | 1s | 053314 | PKR 140.76 | PKR 140.76/vial/unit | 7% above median |
| Mikaray | Amikacin | 500 mg/2 mL | Injection | 1s | 053315 | PKR 258.17 | PKR 258.17/vial/unit | 9% below median |
| Neo-Mercazole | Carbimazole | 5 mg | Tablet | 100's | 000494 | PKR 300.75 | PKR 3.01/tablet | 281% above median |
| Netidin | Netilmicin | 3 mg/mL | Ophthalmic drops | 5ml | 076594 | PKR 431.54 | PKR 86.31/mL | No comparator |
| Nicotrim Forte | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 100s | 005334 | PKR 793.85 | PKR 7.94/tablet | 14% below median |
| Nicotrim PeadiatricSource observed | Trimethoprim | 40 mg | Suspension | 120ml | 112760Official source ↗ | No indexed price | — | — |
| Nicotrim Peadiatric Suspension Trimethoprim +Sulphamethoxazole 40mg/200mgSource observed | — | — | — | 120ml | 112760Official source ↗ | No indexed price | — | — |
| Nixaray | Ciprofloxacin | 250 mg | Tablet | 10's | 112816 | PKR 268.50 | PKR 26.85/tablet | 6% above median |
| Nixaray | Ciprofloxacin | 500 mg | Tablet | 60's | 112817 | PKR 2,390.58 | PKR 39.84/tablet | 7% below median |
| Nixaray | Ciprofloxacin | 500 mg | Tablet | 10's | 112817 | PKR 415.68 | PKR 41.57/tablet | Near median |
| Nixaray | Ciprofloxacin | 500 mg | Tablet | 100's | 112817 | PKR 3,984.30 | PKR 39.84/tablet | 7% below median |
| Nixaray | Ciprofloxacin | 500 mg | Tablet | 14's | 112817 | PKR 580.76 | PKR 41.48/tablet | Near median |
| Nixaray | Ciprofloxacin | 500 mg | Tablet | 50's | 112817 | PKR 1,991.40 | PKR 39.83/tablet | 7% below median |
| Oculol | Dorzolamide + Timolol | 20 mg/mL + 5 mg/mL | Ophthalmic drops | 5 ml | 076591 | PKR 1,459.36 | PKR 291.87/mL | No comparator |
| Ozamine | Olanzapine | 5 mg | Tablet | 10's | 103208 | PKR 155.65 | PKR 15.57/tablet | 15% below median |
| Prednocin 5ml Loteprednol Etabonate + TobbramycinSource observed | — | — | Ophthalmic drops | 5ml×1's | 110322Official source ↗ | No indexed price | — | — |
| Pruine | Aciclovir | 5 % | Ointment | 5gm | 090904 | PKR 157.46 | PKR 31.49/g | 45% below median |
| Prurine | Aciclovir | 400 mg | Tablet | 35's | 112612 | PKR 1,582.19 | PKR 45.21/tablet | 23% below median |
| Quezal | Quetiapine | 25 mg | Tablet | 3x 10's | 105350 | PKR 499.43 | PKR 16.65/tablet | 21% below median |
| Quezal | Quetiapine | 25 mg | Tablet | 1x10's | 105350 | PKR 166.48 | PKR 16.65/tablet | 21% below median |
| Quezal | Quetiapine | 25 mg | Tablet | 2x10's | 105350 | PKR 332.95 | PKR 16.65/tablet | 21% below median |
| Rasimet 10+ Ezitimibe+ | Ezetimibe + Simvastatin | 10 mg + 10 mg | Tablet | 7's | 067221 | PKR 291.87 | PKR 41.70/tablet | 60% below median |
| Rasimet 10+ Ezitimibe+ | Ezetimibe + Simvastatin | 10 mg + 20 mg | Tablet | 7's | 067222 | PKR 1,021.55 | PKR 145.94/tablet | No comparator |
| Rayart | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 2 x 8 | 058254 | PKR 660.90 | PKR 41.31/tablet | 5% above median |
| Rayaz | Azithromycin | 250 mg | Capsule | 1 x 6 | 053292 | PKR 471.13 | PKR 78.52/capsule | 59% above median |
| Rayaz | Azithromycin | 200 mg/5 mL | Dry suspension | 15 ml | 076589 | PKR 345.50 | PKR 23.03/mL | 10% above median |
| Rayaz | Azithromycin | 500 mg | Tablet | 1 x 6 | 076682 | PKR 575.82 | PKR 95.97/tablet | 13% above median |
| Raycan-H | Candesartan + Hydrochlorothiazide | 12.5 mg + 16 mg | Tablet | 28's | 067220 | PKR 1,359.64 | PKR 48.56/tablet | No comparator |
| Raydex T | Tobramycin + Dexamethasone | 3 mg/mL + 1 mg/mL | Ophthalmic drops | 5 ml | 074968 | PKR 244.59 | PKR 48.92/mL | No comparator |
| Raygil | Metronidazole | 200 mg | Tablet | 20 x 10 | 058251 | PKR 534.79 | PKR 2.67/tablet | 25% above median |
| Raygil | Metronidazole | 400 mg | Tablet | 20 x 10 | 058252 | PKR 776.22 | PKR 3.88/tablet | 31% above median |
| Raylox | Levofloxacin | 250 mg | Tablet | 1 x 10 | 053306 | PKR 516.33 | PKR 51.63/tablet | 8% above median |
| Raylox | Levofloxacin | 500 mg | Tablet | 1 x 10 | 053307 | PKR 859.18 | PKR 85.92/tablet | 9% above median |
| Raylox | Levofloxacin | 750 mg | Tablet | 1 x 10 | 076679 | PKR 472.96 | PKR 47.30/tablet | 49% below median |
| Raymal | Artemether | 80 mg/mL | Injection | 1 x 6 | 053316 | PKR 1,028.55 | PKR 171.43/vial/unit | 5% below median |
| Raymal | Artemether | 80 mg | Injection | 1 x 6 | 053316 | PKR 1,028.55 | PKR 171.43/vial/unit | 14% below median |
| Raymox | Moxifloxacin | 400 mg | Tablet | 1 x 5 | 053299 | PKR 690.98 | PKR 138.20/tablet | 25% below median |
| Rayplat | Clopidogrel | 75 mg | Tablet | 1 x 10 | 053293 | PKR 293.15 | PKR 29.32/tablet | 8% above median |
| Raypride-M 1+ | Glimepiride + Metformin | 500 mg + 1 mg | Tablet | 3 x 10's | 067218 | PKR 291.87 | PKR 9.73/tablet | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.